摘要
目的 :观察和探讨 CD7+ 的急性髓细胞性白血病 (AML )表达特征及它们对 AML患者预后的影响。方法 :采用间接免疫荧光法和流式细胞仪对 2 75例初诊的 AML患者进行了免疫表型检测 ,并对淋系分化抗原阳性表达率加髓系分化抗原阳性表达率大于 10 0 %患者的白血病细胞用流式细胞仪做双标记分析。结果 :2 75例 AML患者中 ,3 6例表达淋系分化抗原 CD7(占 13 .1% ) ;诱导化疗疗效方面 ,在同等化疗强度的基础上 ,CD34+ CD7+ AML患者的缓解率明显低于 CD34- CD7- AML 患者 (P<0 .0 5 )。结论 :CD7+ AML 的表达具有复杂性、异质性 ,属于一种预后不良的临床亚型 。
Objective:To further explore the expression of CD 7 + in acute myeloid leukemia(AML)and its impact of on clinical prognosis of patients with AML.Methods:Using indirect immmunofluorescence assay and immunophenotyping was performed in 275 patients with AML.Leukemic cells co-expressing lymphoid and myeloid associated antigens were analysed by dual-color flow cytometry when the two expressing percentages plus more than 100 %.Results:Thirty-six in 275 patients expressed CD 7(13.1 %).Achieve CR 1 is not different.The remission rate(CR) in CD 34 +CD 7 + patients with AML was Lower than CD 34 -CD 7 - patients with AML(P<0.05).Conclusion:Expression of CD 7 + AML showed complexity and heterogeneity,CD 7 +AML patients predict a poor prognosis.Therapic desingn direct to this adverse clinical subtype remains to be explored.
出处
《临床医药实践》
2003年第4期243-245,共3页
Proceeding of Clinical Medicine
基金
山西省卫生厅青年科研基金资助
课题编号 970 2 7
关键词
免疫表型
淋系
急性髓细胞性白血病
预后
immunophenotyping
lymphoid
acute myeloicl leukemia
prognosis
